MiNK Therapeutics, Inc. INKT

INKT Company Overview

MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of allogeneic invariant natural killer T (iNKT) cell therapies for cancer, immune-mediated diseases, and other serious conditions. The company operates within the biotechnology and cell therapy industries and is publicly traded on Nasdaq under the ticker INKT. MiNK’s core business centers on discovering, manufacturing, and advancing off-the-shelf cellular immunotherapies designed to combine the tumor-targeting capabilities of immune cells with potentially lower toxicity profiles compared with certain existing cell therapies.

The company’s primary product platform involves engineered and native iNKT cell therapies, including programs targeting solid tumors and hematologic malignancies. MiNK emerged from research and development efforts associated with Agenus Inc., which remains a significant shareholder and strategic partner. The company has emphasized proprietary manufacturing processes intended to support scalable production of donor-derived iNKT cells. Its positioning in the market is tied to the relative rarity of pure-play iNKT therapeutic developers and its focus on allogeneic cell therapies that may offer logistical and cost advantages over autologous approaches.